Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 21.0
(0.92%)
CNY 21.0
(0.92%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.29 Billion CNY | 66.91% |
| 2022 | 774.45 Million CNY | 131.47% |
| 2021 | 334.57 Million CNY | 568.62% |
| 2020 | 50.04 Million CNY | 0.0% |
| 2019 | - CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.03 Billion CNY | 7.15% |
| 2024 Q1 | 1.89 Billion CNY | 46.8% |
| 2024 Q3 | 2.03 Billion CNY | 0.37% |
| 2023 Q4 | 1.29 Billion CNY | 12.55% |
| 2023 Q3 | 1.14 Billion CNY | 4.21% |
| 2023 FY | 1.29 Billion CNY | 66.91% |
| 2023 Q2 | 1.1 Billion CNY | 13.72% |
| 2023 Q1 | 969.11 Million CNY | 25.14% |
| 2022 Q3 | 620.82 Million CNY | 23.36% |
| 2022 Q4 | 774.45 Million CNY | 24.75% |
| 2022 FY | 774.45 Million CNY | 131.47% |
| 2022 Q2 | 503.27 Million CNY | 14.16% |
| 2022 Q1 | 440.83 Million CNY | 31.76% |
| 2021 Q4 | 334.57 Million CNY | 36.61% |
| 2021 Q2 | 217.38 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 334.57 Million CNY | 568.62% |
| 2021 Q3 | 244.9 Million CNY | 12.66% |
| 2020 Q4 | 50.04 Million CNY | 0.0% |
| 2020 FY | 50.04 Million CNY | 0.0% |
| 2020 Q2 | 50 Million CNY | 0.0% |
| 2019 FY | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |